文献速递炎症性肠病消化内镜

系统综述:纤维狭窄型克罗恩病的药物治疗

Systematic review: medical therapy for fibrostenosing Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-13

该系统综述评估了成人小肠纤维狭窄型克罗恩病(CD)的全身及内镜下病灶内药物治疗疗效,共纳入10项全身治疗研究和8项病灶内注射研究。全身治疗和病灶内治疗的术后切除率分别为28.3%和18.5%,病灶内治疗者重复内镜球囊扩张的风险为58.3%。目前尚无优选治疗方案,乌司奴单抗和维得利珠单抗的数据缺乏。

要点

  • 全身药物和病灶内治疗术后切除率分别为28.3%和18.5%。
  • 病灶内治疗者重复内镜球囊扩张风险达58.3%。
  • 尚无优选治疗,乌司奴单抗和维得利珠单抗数据缺乏。

核心结论

  • 对于纤维狭窄型小肠克罗恩病患者,目前尚无优选的药物治疗方案。
  • 乌司奴单抗和维得利珠单抗的相关数据缺乏。
  • 内镜下病灶内药物注射未能明确预防重复内镜球囊扩张或手术。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、CENTRAL和Scopus数据库。
  • 纳入10项全身药物治疗研究和8项病灶内注射研究。
  • 全身治疗和病灶内注射各仅有一项随机对照试验,其余为观察性研究。

主要发现

  • 全身治疗(均为TNF拮抗剂)术后切除率的合并事件率为28.3%(95%CI:18.2%-41.3%),中位随访23个月(范围5.5-105.8)。
  • 病灶内治疗(除一项英夫利西单抗外均为皮质类固醇)术后切除率的合并事件率为18.5%(95%CI:8.3%-36.2%),中位随访21.8个月(范围5-47)。
  • 病灶内治疗者重复内镜球囊扩张的风险为58.3%(95%CI:36.6%-77.3%),中位随访21.8个月(范围5-47)。

临床怎么用

  • 临床决策时需认识到纤维狭窄型小肠克罗恩病缺乏优选药物,全身和病灶内治疗证据有限。
  • 与患者沟通时,可参考术后切除率和重复扩张风险的数据,但需注意证据多来自观察性研究。

局限性

  • 多数研究为观察性研究,随机对照试验仅各一项。
  • 全身治疗研究仅涉及TNF拮抗剂,未涵盖乌司奴单抗和维得利珠单抗。
  • 病灶内治疗研究除一项英夫利西单抗外均使用皮质类固醇,药物种类有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medical therapy and/or endoscopic balloon dilation with intralesional therapies are options for the treatment of small bowel fibrostenotic Crohn's disease (CD). AIM: To perform a systematic review summarising evidence for efficacy of systemic and endoscopic intralesional medical therapy in established small bowel strictures in adult CD patients. METHODS: A systematic search of MEDLINE, EMBASE, CENTRAL and Scopus was conducted. Primary outcomes were rates of surgical resection and repeat endoscopic dilation. Pooled event rates from random effects models across studies with 95% confidence intervals were reported. RESULTS: Ten studies describing systemic medical therapy and eight studies of intralesional injection were included. One randomised controlled trial each for systemic therapy and intrastricture injection were identified. Only observational studies were found for systemic biologic therapies, which exclusively included tumour necrosis factor (TNF) antagonists, while intralesional therapies all involved corticosteroids except for one study that evaluated infliximab. Pooled event rates for surgical resection after systemic and intralesional therapy were 28.3% (95% CI: 18.2%-41.3%) and 18.5% (95% CI: 8.3%-36.2%), respectively over a median follow-up of 23 months (range 5.5-105.8), and 21.8 months (range 5-47). Risk of repeat endoscopic balloon dilation in those with intralesional therapy was 58.3% (95% CI: 36.6%-77.3%) over a median follow-up of 21.8 months (range 5-47). CONCLUSIONS: There are no favoured therapies for patients with stricturing small bowel CD. Data are lacking for ustekinumab and vedolizumab. No endoscopic intralesional medications provided a clear benefit for prevention of repeat EBD or surgery.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn's disease. Aliment Pharmacol Ther. 2020. PMID: 32406116. doi:10.1111/apt.15750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。